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Using three antisera to neurotensin of defined regional specificity, a novel neurotensin has been identified 
in extracts of guinea pig brain and small intestine. The primary structure of the peptide was established 
as: pGlu Leu Tyr Glu Asn Lys Ser Arg Arg Pro Tyr Be Leu. Guinea pig neurotensin differs from bovine 
neurotensin by substitution of a prolyl residue by a seryl residue at position 7. Synthetic [Ser7]neurotensin 
showed identical chromatographic and immunochemical properties to guinea pig neurotensin. This differ- 
ence in primary structure may account for some of the anomalous pharmacological effects of bovine neu- 
rotensin on guinea pig tissues. 
Neurotensin (Guinea pig) Gastrointestinal peptide Primary structure HPLC Radioimmunoassay 
1. INTRODUCTION 2. MATERIALS AND METHODS 
The tridecapeptide, neurotensin, was originally 
isolated from bovine hypothalamus [l] and shown 
to possess limited homology to the amphibian pep- 
tide, xenopsin [2]. A peptide identical to 
hypothalamic neurotensin was subsequently 
isolated from bovine intestine [3] and im- 
munocytochemical and radioimmunoassay studies 
have confirmed a dual brain/gut distribution in 
other mammals [4,5]. Using antisera of defined 
regional specificity in radioimmunoassays, 
evidence was obtained that the primary structure 
of neurotensin is probably conserved in the 
human, dog, rat and pig [6,7]. In the guinea pig, 
many otherwise highly conserved regulatory pep- 
tides, e.g. insulin [8], glucagon [9], vasoactive in- 
testinal peptide [lo], cholecystokinin-octapeptide 
[l l] and gastrin [12] possess appreciably different 
primary structures. Here, we report the presence of 
a novel neurotensin, [Ser’hreurotensin in extracts 
of guinea pig brain and small intestine and 
characterization of the peptide from the gut. 
* To whom correspondence should be addressed 
2.1. Isolation procedures 
The entire small intestine (607 g) and brain 
(90 g) from 40 fed, anaesthetized guinea pigs were 
separately homogenized at 4°C with 8 ml/g 
ethanol/O.7 M HCI (3: 1, v/v) using a Waring 
blender. The homogenates were stirred overnight 
at 4”C, centrifuged (20000 x g for 1 h) and 
ethanol removed from the supernatants under 
reduced pressure. An aliquot of each solution was 
removed for gel-permeation chromatography and 
radioimmunoassay. After further centrifugation 
(20000 x g for 1 h), trifluoroacetic acid was added 
to the supernatants to a final concentration of 
0.1% (v/v) and the solutions pumped at a flow rate 
of 10 ml/h through 8 Sep-pak Cl8 cartridges 
(Waters Associates) connected in series. Bound 
material was eluted with acetonitrile/water/tri- 
fluoroacetic acid (70.0 : 28.9 : 0.1) and the effluent 
lyophilized. 
2.2. Gel-permeation chromatography 
Aliquots (5 ml) of extracts of brain and small in- 
testine were chromatographed on a column (100 x 
2.5 cm) of Sephadex G-50 (fine) equilibrated with 
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1 M acetic acid. The column was eluted at a flow scribed [13]. Guinea pig neurotensin (approx. 
rate of 25 ml/h and fractions (5 ml) collected. Ali- 1 nmol) was incubated with L-pyroglutamyl- 
quots (500~1) of each fraction were lyophilized, peptide hydrolase (EC 3.4.11.8) (Boehringer, 
reconstituted in 50 mM sodium phosphate buffer Mannheim) according to [14]. The primary struc- 
(pH 7.4) containing 140 mM NaCl and 0.2% (w/v) ture of guinea pig des[pGlu’]neurotensin was 
bovine serum albumin and subjected to region- determined by automated Edman degradation 
specific radioimmunoassay. The column was using an Applied Biosystems model 470A gas- 
calibrated with blue dextran ( VO), synthetic bovine phase sequencer [ 151. The detection limit for PTH- 
neurotensin @NT) and potassium chromate (K). amino acids was 0.5 pmol. 
2.3. High-performance liquid chromatography 2.5. Radioimmunoassay methods 
The intestinal extracts, after Sep-pak concentra- 
tion, were redissolved in 0.1% (v/v) trifluoroacetic 
acid (1 ml) and injected onto a column (25 x 1 cm) 
of Ultrasphere-ODS (Beckman Instruments) 
equipped with a Spherisorb-ODS guard column. 
The column was eluted at a flow rate of 
2.5 ml/min with a linear gradient (total volume 
150 ml) formed from water/trifluoroacetic acid 
(99.9 : 0.1) and acetonitrile/water/trifluoroacetic 
acid (42.0: 57.9: 0.1). Fractions (1 min) were col- 
lected and the UV absorbance measured at 
214 nm. Neurotensin-like immunoreactivity (NT- 
LI) in the fractions was measured at a dilution of 
1 : 100 using the C-terminally directed antiserum 
NT 6. 
The fraction containing maximum NT-L1 was 
lyophilized, redissolved in 0.1% (v/v) trifluoro- 
acetic acid (1 ml) and injected onto a Supelcosil 
LC3DP column (250 x 4.6 mm) (Supelco). The 
column was eluted at a flow rate of 1.5 ml/min 
with a linear gradient (7.5 ml) formed from 
water/trifluoroacetic acid (99.9 : 0.1) and acetoni- 
trile/water/trifluoroacetic acid (21 .O : 78.9 : 0.1) 
followed by a linear gradient (90 ml) to acetoni- 
trile/water/trifluoroacetic acid (35.0: 64.9 : 0.1). 
Peaks of UV-absorbing material were collected 
manually and assayed as previously. The peak of 
NT-L1 was chromatographed on a Supelcosil 
LC-18-DB column (250 x 4.6 mm) eluted at a 
flow rate of 1.5 ml/min with a linear gradient 
(15 ml) formed from water/trifluoroacetic acid 
(99.9 : 0.1) and acetonitrile/water/trifluoroacetic 
acid (16.5 :83.4: 0.1) followed by a linear gradient 
(45 ml) to acetonitrile/water/trifluoroacetic acid 
(28.0:71.9:0.1). 
NT-L1 was determined using three antisera to 
neurotensin of defined regional specificity ac- 
cording to [ 16,171. Antiserum NT6 is directed 
towards the C-terminal region of neurotensin and 
shows full cross-reactivity with neurotensin (8- 13) 
but no detectable cross-reactivity with neurotensin 
(l-8) and neurotensin (l-11). Antiserum GNT-21 
is directed towards a site in the N-terminal to cen- 
tral region of the molecule and shows full cross- 
reactivity towards neurotensin (l-8) and neuroten- 
sin (l-11) but approx. 3% with neurotensin (l-6). 
Antiserum NT3 is directed towards a conforma- 
tion existing in intact neurotensin and shows 1% 
cross-reactivity with neurotensin (2- 13) and 18% 
cross-reactivity with neurotensin (8-13). Antisera 
of similar specificity have been described by others 
[61. 
2.6. Synthesis of guinea pig neurotensin 
[Ser7]neurotensin was synthesized by the solid- 
phase method of [18] using the Cambridge 
Research Biochemicals Pepsynthesiser and 
purified by reverse-phase HPLC under the condi- 
tions described previously. 
3. RESULTS 
3.1. NT-LI in guinea pig tissues 
2.4. Structural analysis 
Amino acid composition was determined in 
duplicate using approx. 1 nmol peptide as de- 
The concentrations of neurotensin measured 
with the three regionally specific antisera in ex- 
tracts of guinea pig brain and gut are shown in 
table 1. The total content of neurotensin in the in- 
testinal extract, determined with C-terminally 
directed antiserum NT6, was 11 nmol. The NT-L1 
in both brain and gut extracts was eluted from a 
Sephadex G-50 gel permeation column as a single 
peak with the same elution volume as bovine 
neurotensin (fig.1). The ratios of immunoreac- 
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Table 1 
Concentration of neurotensin-like immunoreactivity 
(pmol/g wet wt tissue) in extracts of guinea pig brain and 
small intestine measured with regionally specific antisera 
Antiserum Brain Small intestine 
NT6 9.60 18.10 
GNT 21 0.23 1.57 
NT3 3.90 3.48 
Fig.1. Elution profile on Sephadex G-50 of the 
neurotensin-like immunoreactivity in extracts of guinea 
pig. (A) Whole brain, (B) small intestine. Fractions were 
assayed with regionally specific antisera to neurotensin: 
NT 6 (M), NT 3 (H) and GNT 21 (M). 
Elution conditions and antisera specificities are 30 40 50 60 70 80 90 00 1x1 
described in the text. FRACTION NO 
lo 20 a a 50 
TIME (mm) - 
Fig.2. Reverse-phase HPLC on a semi-preparative Ultrasphere-ODS column of extracts of guinea pig small intestine, 
after concentration on Sep-Pak Cl8 cartridges. The bar indicates the fraction with maximum neurotensin-like 
immunoreactivity determined with antiserum NT 6. (-) Concentration of acetonitrile in the elution solvent. 
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tivities measured with the three regionally specific 
antisera were the same in the chromatographic 
peaks as in the crude extracts. 
3.2. Purification of the peptide 
Using the semi-preparative reverse-phase HPLC 
column (fig.2), the NT-L1 in the Sep-pak concen- 
trated extract of guinea pig gut was eluted as a 
single major peak with retention time between 29 
and 30 min (synthetic bovine neurotensin 
29.5 min). After rechromatography of this peak 
on a diphenylmethylsilylsilica column (fig.3), NT- 
LI was associated with a single, sharp peak of UV- 
absorbing material. This component was purified 
to homogeneity by chromatography on an 
analytical octadecyldimethylsilylsilica column 
(fig.4). Guinea pig neurotensin was eluted as a 
symmetrical peak with retention time 37.2 min 
compared with a retention time of 38.8 min for 
bovine neurotensin. The absorbance at 280 nm in- 
dicated the presence of tyrosine and/or tryptophan 
residues in the peptide. The yield of guinea pig 
neurotensin was 2.8 nmol representing 26% of 
that in the original extract. 
3.3. Structural analysis 
Amino acid analysis of guinea pig neurotensin 
(table 2) indicated that the peptide differed from 
o.oJ I 0 m XI a 
TIME Imml - 
Fig.3. Reverse-phase HPLC of partially purified guinea 
pig neurotensin on a Supelcosil LC-3DP column. The 
peak with neurotensin-like immunoreactivity is indicated 
by the bar. (-) Concentration of acetonitrile in the 
elution solvent. 
Fig.4. Purification to homogeneity of guinea pig 
neurotensin (r) on a Supelcosil LC-18-DB column. 
Absorbance was measured at (A) 280 nm and (B) 
214 nm. (-) Concentration of acetonitrile in the 
elution solvent. The arrow indicates the retention time of 
synthetic bovine neurotensin. 
Table 2 
Amino acid compositions of guinea pig neurotensin and 
synthetic [Ser’lneurotensin 
Residue Relative amount 
Guinea pig [Ser’Jneurotensin 
neurotensin 
Asx 1.12 1.00 
Ser 1.33 0.89 
Glx 2.33 2.39 
Pro 1.14 0.71 
Be 0.87 0.93 
Leu 1.97 1.99 
TYr 1.99 1.97 
LYS 0.95 1.02 
Arg 1.83 2.10 
Data represent he means of two determinations 
bovine neurotensin by loss of a prolyl residue and 
gain of a seryl residue. Treatment with 
pyroglutamyl aminopeptide resulted in a signifi- 
cant decrease in the retention time on HPLC of the 
product, indicating the presence of a pyroglutamyl 
residue at the N-terminus of the peptide. Unam- 
biguous assignation of residues (1-12) of guinea 
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Table 3 
Automated Edman degradation of guinea pig 
des[pyroglutamyl’]neurotensin 
Cycle no. PTH-amino acid Yield (pmol) 
1 Leu 647 
2 Tyr 703 
3 Glu 167 
4 Asn 708 
5 LYS 499 
6 Ser 167 
7 Arg 183 
8 Arg 266 
9 Pro 374 
10 Tyr 287 
11 Be 161 
12 Leu 107 
The repetitive yield was 89.4% calculated from Tyr’ and 
Tyr” 
pig des[pGlu’]neurotensin was possible by 
automated Edman degradation (table 3) and the 
sequence analysis indicated that the prolyl residue 
at position 7 of the bovine neurotensin sequence 
had been substituted by a seryl residue. The struc- 
ture of guinea pig neurotensin was confirmed by 
chemical synthesis. Synthetic [Ser’]neurotensin 
(amino acid composition shown in table 2) was 
eluted from a reverse-phase HPLC column with 
the same retention time as guinea pig neurotensin 
under the elution conditions shown in fig.4. The 
reactivities of the synthetic and natural peptides 
towards the regionally specific antisera were 
similar (antiserum NT6, natural lOO%, synthetic 
100%; antiserum GNT-21, natural 6.6%, synthetic 
4.8%; antiserum NT3, natural 15.6%, synthetic 
13.0%). 
4. DISCUSSION 
The isolation of [Ser’]neurotensin from guinea 
pig gut has provided the first evidence that the 
primary structure of neurotensin is not fully con- 
served in mammals. The substitution of a prolyl 
residue in bovine neurotensin for a seryl residue in 
the guinea pig requires only a single base change in 
the corresponding DNA sequence. In chicken 
neurotensin, the C-terminal hexapeptide sequence 
is conserved but three substitutions occur in the N- 
terminal region [ 191. The substitution of Pro’ for 
Ala’ in chicken neurotensin also requires only a 
single base change in the codon. The im- 
munochemical properties of guinea pig neuroten- 
sin are consistent with its proposed structure. 
Strong reactivity towards antiserum NT 6 is to be 
expected from the conservation of the C-terminal 
region of the molecule. Markedly reduced reactivi- 
ty towards antiserum GNT-21 suggests that the 
prolyl residue at position 7 is important in the 
binding of neurotensin to this antiserum. As an- 
tiserum NT 3 requires a determinant hat exists on- 
ly in the intact neurotensin molecule for full ex- 
pression of binding [la], the reduced reactivity of 
guinea pig neurotensin [comparable to that of the 
(8-13) fragment] suggests that the peptide adopts 
an appreciably different conformation to that of 
bovine neurotensin. 
Neurotensin exerts a powerful pharmacological 
effect upon gastrointestinal motility in mammals. 
The predominant effect in vivo is the inhibition of 
peristaltic activity. Studies in vitro have shown that 
bovine neurotensin exerts an anomalous effect 
upon the guinea pig gastrointestinal tract. Thus, 
neurotensin induces relaxation of the rat 
duodenum [l] and ileum [20] but causes contrac- 
tion of the guinea pig ileum [1,20] and taenia coli 
[20]. Although the guinea pig ileum has been used 
extensively for structure-activity studies of 
neurotensin and its analogues, the present study 
supports the conclusion [21] that this species is in- 
appropriate for the study of neurotensin phar- 
macology. The availability of synthetic [Ser’]- 
neurotensin will permit an investigation of the 
biological effects of this peptide in the guinea pig. 
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